[Plasmapheresis as treatment for severe hypertriglyceridemia].
作者信息
Manrique Franco Katty, Sánchez-Vilar Burdiel Olga, Aragón Valera Carmen, Sánchez Fernández M Soledad, Rovira Loscos Adela
出版信息
Endocrinol Nutr. 2011 Jun-Jul;58(6):319-20. doi: 10.1016/j.endonu.2010.12.007. Epub 2011 Apr 1.
PMID:21459058
Abstract
摘要
相似文献
1
[Plasmapheresis as treatment for severe hypertriglyceridemia].
Endocrinol Nutr. 2011 Jun-Jul;58(6):319-20. doi: 10.1016/j.endonu.2010.12.007. Epub 2011 Apr 1.
2
Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Diabetes Obes Metab. 2009 May;11 Suppl 2:1-2. doi: 10.1111/j.1463-1326.2008.01032.x.
3
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Diabetes Care. 2007 Apr;30(4):890-5. doi: 10.2337/dc06-1732. Epub 2007 Feb 2.
4
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Horm Metab Res. 2007 Nov;39(11):826-9. doi: 10.1055/s-2007-991172.
5
Three new drugs for type 2 diabetes.
Drug Ther Bull. 2008 Jul;46(7):49-52. doi: 10.1136/dtb.2008.06.0014.
6
[Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
J Pharm Belg. 2009 Jun(2):64-6.
7
Case 2. Recurrence of myocardial infarction.
Can J Cardiol. 2000 Aug;16 Suppl E:24E-26E.
8
Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
Prescrire Int. 2008 Oct;17(97):188.
9
Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia.
JOP. 2010 Sep 6;11(5):467-9.
10
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Pharm Unserer Zeit. 2010 Mar;39(2):114-8. doi: 10.1002/pauz.201000358.
Zotero 插件